Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

NCT00903422 ·Status: COMPLETED ·Phase: PHASE1

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

NCT00413283 ·Status: COMPLETED ·Phase: PHASE2

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

NCT02920541 ·Status: COMPLETED ·Phase: PHASE1

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT05673057 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma

NCT04673266 ·Status: COMPLETED ·Phase: PHASE2

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

NCT07107126 ·Status: RECRUITING ·Phase: PHASE1

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

NCT01890746 ·Status: COMPLETED ·Phase: PHASE2

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

NCT04906031 ·Status: UNKNOWN ·Phase: PHASE2

Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia

NCT04095936 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

NCT03541369 ·Status: TERMINATED ·Phase: PHASE1

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT00003123 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867 ·Status: RECRUITING ·Phase: PHASE2

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.

NCT03343847 ·Status: WITHDRAWN ·Phase: PHASE3

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

NCT03957876 ·Status: TERMINATED ·Phase: PHASE2

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00062075 ·Status: COMPLETED ·Phase: PHASE2

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

NCT01261312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT01550185 ·Status: TERMINATED ·Phase: PHASE1

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

NCT01513317 ·Status: TERMINATED ·Phase: PHASE2

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

NCT05367401 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

NCT01773408 ·Status: COMPLETED ·Phase: PHASE1

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT04402541 ·Status: COMPLETED ·Phase: PHASE1

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT01349049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

NCT01380756 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

NCT05246384 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

NCT02098967 ·Status: COMPLETED ·Phase: PHASE1